To the best of our knowledge, the sensitivity of Sel-Cap liquid biopsy is the highest among all liquid biopsy platforms on record for EGFR mutations in early-stage NSCLC, and Sel-Cap shows one of the highest sensitivities for overall disease stage, which is comparable to ddPCR, currently regarded as the most sensitive liquid biopsy to date [16,17]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.